CELLINK

CELLINK is a pioneering biotechnology company based in Sweden that is shaping the future of healthcare. Through its parent company, BICO, CELLINK has established itself as a global leader in bioconvergence, enabling breakthroughs in the field of 3D bioprinting. The company democratized access to advanced research tools by introducing the first universal bioink in 2016, a move that catalyzed the exponential growth of the 3D bioprinting industry, now valued at $1 billion. By offering an extensive range of bioinks, bioprinters, software, and services, CELLINK has garnered the trust of leading researchers and top 20 pharmaceutical companies worldwide, with over 1,000 laboratories embracing its cutting-edge innovations. These groundbreaking solutions have been referenced in 700 publications, underscoring their significant impact on the scientific community. In March 2020, CELLINK secured a notable kr2.00M grant investment from Vinnova, further reinforcing its position as a trailblazer in the biotechnology landscape. As part of the BICO bioconvergence movement, CELLINK is dedicated to realizing the potential of on-demand bioprinting of human organs and tissues, thereby shaping the future of health.